Departments of Urology, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
Curr Oncol. 2023 Aug 1;30(8):7286-7302. doi: 10.3390/curroncol30080529.
Theranostics (therapy + diagnosis) targeting prostate-specific membrane antigen (PSMA) is an emerging therapeutic modality that could alter treatment strategies for prostate cancer. Although PSMA-targeted radioligand therapy (PSMA-RLT) has a highly therapeutic effect on PSMA-positive tumor tissue, the efficacy of PSMA-RLT depends on PSMA expression. Moreover, predictors of treatment response other than PSMA expression are under investigation. Therefore, the optimal patient population for PSMA-RLT remains unclear. This review provides an overview of the current status of theranostics for prostate cancer, focusing on PSMA ligands. In addition, we summarize various findings regarding the efficacy and problems of PSMA-RLT and discuss the optimal patient for PSMA-RLT.
靶向前列腺特异性膜抗原（PSMA）的治疗与诊断（theranostics，therapy + diagnosis）是一种新兴的治疗方法，可能会改变前列腺癌的治疗策略。虽然 PSMA 靶向放射性配体治疗（PSMA-RLT）对 PSMA 阳性肿瘤组织具有高度的治疗效果，但 PSMA-RLT 的疗效取决于 PSMA 的表达。此外，正在研究除 PSMA 表达以外的治疗反应预测因子。因此，PSMA-RLT 的最佳患者人群尚不清楚。本综述概述了前列腺癌的治疗与诊断现状，重点介绍了 PSMA 配体。此外，我们总结了关于 PSMA-RLT 的疗效和问题的各种发现，并讨论了 PSMA-RLT 的最佳患者。
